Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial LANCET RHEUMATOLOGY Chung, L., Spino, C., McLain, R., Johnson, S. R., Denton, C. P., Molitor, J. A., Steen, V. D., Lafyatis, R., Simms, R. W., Kafaja, S., Frech, T. M., Hsu, V., Domsic, R. T., Pope, J. E., Gordon, J. K., Mayes, M. D., Sandorfi, N., Hant, F. N., Bernstein, E. J., Chatterjee, S., Castelino, F. V., Ajam, A., Allanore, Y., Matucci-Cerinic, M., Whitfield, M. L., Distler, O., Singer, O., Young, A., Nagaraja, V., Fox, D. A., Furst, D. E., Khanna, D. 2020; 2 (12): E743–E753

View details for DOI 10.1016/S2665-9913(20)30237-X

View details for Web of Science ID 000595474100011